{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:55:20Z","timestamp":1790704520905,"version":"4.1.0"},"reference-count":226,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>Prostate cancer (PC) is the third most common male cancer in the world, which occurs due to various mutations leading to the loss of chromatin structure. There are multiple treatments for this type of cancer, of which chemotherapy is one of the most important. Sometimes, a combination of different treatments, such as chemotherapy, radiotherapy, and surgery, are used to prevent tumor recurrence. Among other treatments, androgen deprivation therapy (ADT) can be mentioned, which has had promising results. One of the drawbacks of chemotherapy and ADT treatments is that they are not targeted to the tumor tissue. For this reason, their use can cause extensive side effects. Treatments based on nanomaterials, known as nanomedicine, have attracted much attention today. Nanoparticles (NPs) are one of the main branches of nanomedicine, and they can be made of different materials such as polymer, metal, and carbon, each of which has distinct characteristics. In addition to NPs, nanovesicles (NVs) also have therapeutic applications in PC. In treating PC, synthetic NVs (liposomes, micelles, and nanobubbles) or produced from cells (exosomes) can be used. In addition to the role that NPs and NVs have in treating PC, due to being targeted, they can be used to diagnose PC and check the treatment process. Knowing the characteristics of nanomedicine-based treatments can help design new treatments and improve researchers\u2019 understanding of tumor biology and its rapid diagnosis. In this study, we will discuss conventional and nanomedicine-based treatments. The results of these studies show that the use of NPs and NVs in combination with conventional treatments has higher efficacy in tumor treatment than the individual use of each of them.<\/jats:p>","DOI":"10.3389\/fbioe.2024.1444201","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T19:14:16Z","timestamp":1724354056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Nanomedicines in diagnosis and treatment of prostate cancers: an updated review"],"prefix":"10.3389","volume":"12","author":[{"given":"Jiajia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2174\/18755666mta5dnju2w","article-title":"Darolutamide as a second-generation androgen receptor inhibitor in the treatment of prostate cancer","volume":"21","author":"Abbasi","year":"2021","journal-title":"Curr. Mol. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"175267","DOI":"10.1016\/j.ejphar.2022.175267","article-title":"Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function","volume":"933","author":"Abbaspour-Aghdam","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4103\/0976-500x.119704","article-title":"Cabazitaxel: a novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects","volume":"4","author":"Abidi","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B4","first-page":"4761","article-title":"Response of prostate cancer to anti-Her-2\/neu antibody in androgen-dependent and-independent human xenograft models","volume":"59","author":"Agus","year":"1999","journal-title":"Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1039\/c3ra47370h","article-title":"Polymeric micelles as drug delivery vehicles","volume":"4","author":"Ahmad","year":"2014","journal-title":"Rsc Adv."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4172\/2167-065X.1000e114","article-title":"Micelles: chemotherapeutic drug delivery","volume":"2","author":"Al-Achi","year":"2013","journal-title":"Clin. Pharmacol. and Biopharm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4172\/2161-0525.1000384","article-title":"Gold and silver nanoparticles: synthesis methods, characterization routes and applications towards drugs","volume":"6","author":"Alaqad","year":"2016","journal-title":"J. Environ. Anal. Toxicol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"104047","DOI":"10.1016\/j.amsu.2022.104047","article-title":"Jemperli (Dostarlimab-gxly): an unprecedented cancer trial","volume":"79","author":"Ali","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.2147\/ijn.s145096","article-title":"Human mesenchymal stem cell-derived iron oxide exosomes allow targeted ablation of tumor cells via magnetic hyperthermia","volume":"12","author":"Altanerova","year":"2017","journal-title":"Int. J. Nanomedicine."},{"key":"B10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1208\/s12248-012-9344-7","article-title":"A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding","volume":"14","author":"An","year":"2012","journal-title":"AAPS J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"13248","DOI":"10.1021\/am4042367","article-title":"Peroxidase-like activity of Fe3O4@ carbon nanoparticles enhances ascorbic acid-induced oxidative stress and selective damage to PC-3 prostate cancer cells","volume":"5","author":"An","year":"2013","journal-title":"ACS Appl. Mater. and interfaces."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.4049\/jimmunol.172.4.2126","article-title":"Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I\/peptide complexes to dendritic cells","volume":"172","author":"Andr\u00e9","year":"2004","journal-title":"J. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/jco.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arabjc.2010.08.022","article-title":"Carbon nanotubes, science and technology part (I) structure, synthesis and characterisation","volume":"5","author":"Aqel","year":"2012","journal-title":"Arabian J. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aca.2015.03.025","article-title":"Characterisation and determination of fullerenes: a critical review","volume":"882","author":"Astefanei","year":"2015","journal-title":"Anal. Chim. Acta"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/jpm8010006","article-title":"Polymer therapeutics: biomarkers and new approaches for personalized cancer treatment","volume":"8","author":"Atkinson","year":"2018","journal-title":"J. Personalized Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejon.2008.10.003","article-title":"Docetaxel-related side effects and their management","volume":"13","author":"Baker","year":"2009","journal-title":"Eur. J. Oncol. Nurs."},{"key":"B19","doi-asserted-by":"publisher","first-page":"13772","DOI":"10.1038\/s41598-019-50172-6","article-title":"Semen miRNAs contained in exosomes as non-invasive biomarkers for prostate cancer diagnosis","volume":"9","author":"Barcel\u00f3","year":"2019","journal-title":"Sci. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.actbio.2020.06.019","article-title":"Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy","volume":"113","author":"Barve","year":"2020","journal-title":"Acta biomater."},{"key":"B21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jconrel.2015.07.030","article-title":"Using exosomes, naturally-equipped nanocarriers, for drug delivery","volume":"219","author":"Batrakova","year":"2015","journal-title":"J. Control. Release"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3390\/jcm9061894","article-title":"CAR-T cell therapy\u2014an overview of targets in gastric cancer","volume":"9","author":"B\u0119bnowska","year":"2020","journal-title":"J. Clin. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1089\/104303401750195854","article-title":"Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology","volume":"12","author":"Belldegrun","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12645-019-0055-y","article-title":"Nanomedicine review: clinical developments in liposomal applications","volume":"10","author":"Beltr\u00e1n-Gracia","year":"2019","journal-title":"Cancer Nanotechnol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature09744","article-title":"The genomic complexity of primary human prostate cancer","volume":"470","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/s0022-5347(05)64163-8","article-title":"Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer","volume":"168","author":"Berry","year":"2002","journal-title":"J. urology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1056\/nejmoa043739","article-title":"Radical prostatectomy versus watchful waiting in early prostate cancer","volume":"352","author":"Bill-Axelson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3892\/or_00000440","article-title":"Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer","volume":"22","author":"Bode","year":"2009","journal-title":"Oncol. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.crhy.2011.06.001","article-title":"Nanomedicine, nanotechnology in medicine","volume":"12","author":"Boisseau","year":"2011","journal-title":"Comptes Rendus Phys."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","article-title":"Active targeting schemes for nanoparticle systems in cancer therapeutics","volume":"60","author":"Byrne","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1117\/12.2005064","article-title":"Carbon nanoparticles as a multimodal thermoacoustic and photoacoustic contrast agent","volume-title":"Photons plus ultrasound: imaging and sensing 2013","author":"Cai","year":"2013"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1039\/c7nr07450f","article-title":"Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona","volume":"10","author":"Caracciolo","year":"2018","journal-title":"Nanoscale"},{"key":"B33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","article-title":"Early detection of prostate cancer: AUA Guideline","volume":"190","author":"Carter","year":"2013","journal-title":"J. Urology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ng.370","article-title":"Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate","volume":"41","author":"Carver","year":"2009","journal-title":"Nat. Genet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1073\/pnas.1002143107","article-title":"Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity","volume":"107","author":"Chanda","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.23736\/s0393-2249.19.03365-4","article-title":"Precision prostate cancer surgery: an overview of new technologies and techniques","volume":"71","author":"Checcucci","year":"2019","journal-title":"Minerva Urologica e Nefrologica= Italian J. Urology Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"110181","DOI":"10.1016\/j.biopha.2020.110181","article-title":"Anti prostate cancer therapy: aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles","volume":"127","author":"Chen","year":"2020","journal-title":"Biomed. and Pharmacother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"121465","DOI":"10.1016\/j.lfs.2023.121465","article-title":"The effect of mesenchymal stem cell-derived supernatant nasal administration on lung inflammation and immune response in BCG-vaccinated BALB\/c mice","volume":"317","author":"Chenari","year":"2023","journal-title":"Life Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1021\/acs.nanolett.8b01071","article-title":"Sequentially responsive therapeutic peptide assembling nanoparticles for dual-targeted cancer immunotherapy","volume":"18","author":"Cheng","year":"2018","journal-title":"Nano Lett."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1002\/cam4.3016","article-title":"Metabolomic effects of androgen deprivation therapy treatment for prostate cancer","volume":"9","author":"Chi","year":"2020","journal-title":"Cancer Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ijpharm.2017.07.018","article-title":"Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy","volume":"529","author":"Choudhury","year":"2017","journal-title":"Int. J. Pharm."},{"key":"B42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrurol.2014.243","article-title":"Emerging mechanisms of enzalutamide resistance in prostate cancer","volume":"11","author":"Claessens","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/ijms21030869","article-title":"Cationic polymer nanoparticles-mediated delivery of miR-124 impairs tumorigenicity of prostate cancer cells","volume":"21","author":"Conte","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/107327480100800203","article-title":"Prostate cancer: screening and early detection","volume":"8","author":"Cookson","year":"2001","journal-title":"Cancer control."},{"key":"B45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1634\/theoncologist.9-suppl_2-24","article-title":"Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience","volume":"9","author":"Crown","year":"2004","journal-title":"Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40364-022-00398-w","article-title":"Molecular mechanisms and clinical applications of exosomes in prostate cancer","volume":"10","author":"Cui","year":"2022","journal-title":"Biomark. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"16612","DOI":"10.1073\/pnas.1208312109","article-title":"Functionalized multiwalled carbon nanotubes as ultrasound contrast agents","volume":"109","author":"Delogu","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrclinonc.2018.27","article-title":"Cancer immunotherapy and the value of cure","volume":"15","author":"Del Paggio","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jcb.25611","article-title":"c\u2010Src, insulin\u2010like growth factor I receptor, G\u2010protein\u2010coupled receptor kinases and focal adhesion kinase are enriched into prostate cancer cell exosomes","volume":"118","author":"DeRita","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser","year":"2023","journal-title":"Cancer cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/nejmoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.2147\/ijn.s257522","article-title":"Carbon Nanospheres exert antitumor effects associated with downregulation of 4E-BP1 expression on prostate Cancer","volume":"15","author":"Dong","year":"2020","journal-title":"Int. J. Nanomedicine."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0305-7372(83)90016-6","article-title":"Molecular and biochemical pharmacology of mitoxantrone","volume":"10","author":"Durr","year":"1983","journal-title":"Cancer Treat. Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2003.08.010","article-title":"HER2 and COX2 expression in human prostate cancer","volume":"40","author":"Edwards","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1200\/jco.1985.3.6.827","article-title":"A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma","volume":"3","author":"Eisenberger","year":"1985","journal-title":"J. Clin. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"9007","DOI":"10.2147\/ijn.s216972","article-title":"<p>The in vitro immunomodulatory effects of gold nanoparticles synthesized from <em>Hypoxis hemerocallidea<\/em> aqueous extract and hypoxoside on macrophage and natural killer cells<<\/p>","volume":"14","author":"Elbagory","year":"2019","journal-title":"Int. J. Nanomedicine."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/4927312","article-title":"Cancer nanomedicine: a new era of successful targeted therapy","volume":"2019","author":"El-Readi","year":"2019","journal-title":"J. Nanomater."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3762\/bjnano.8.132","article-title":"Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation","volume":"8","author":"Erdmann","year":"2017","journal-title":"Beilstein J. Nanotechnol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/1873-3468.13487","article-title":"Urinary exosomal proteins as (pan\u2010) cancer biomarkers: insights from the proteome","volume":"593","author":"Erozenci","year":"2019","journal-title":"FEBS Lett."},{"key":"B60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","article-title":"Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort B study","volume":"82","author":"Evan","year":"2022","journal-title":"Eur. Urol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.2147\/ijn.s112951","article-title":"Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles","volume":"11","author":"Fan","year":"2016","journal-title":"Int. J. nanomedicine."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9186583","article-title":"Aptamer-conjugated multifunctional polymeric nanoparticles as cancer-targeted, MRI-ultrasensitive drug delivery systems for treatment of castration-resistant prostate cancer","volume":"2020","author":"Fang","year":"2020","journal-title":"BioMed Res. Int."},{"key":"B63","doi-asserted-by":"publisher","first-page":"10781552241265058","DOI":"10.1177\/10781552241265058","article-title":"Dostarlimab: a promising new PD-1 inhibitor for cancer immunotherapy","author":"Farzeen","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B64","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur. Urol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/nejmoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1158\/0008-5472.can-08-3529","article-title":"Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF","volume":"69","author":"Fong","year":"2009","journal-title":"Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cherd.2022.11.013","article-title":"Fundamentals and applications of nanobubbles: a review","volume":"189","author":"Foudas","year":"2023","journal-title":"Chem. Eng. Res. Des."},{"key":"B68","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1212\/wnl.63.12_suppl_6.s15","article-title":"Mechanism of action of mitoxantrone","volume":"63","author":"Fox","year":"2004","journal-title":"Neurology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3390\/cancers12082300","article-title":"Exosomes-mediated transfer of Itga2 promotes migration and invasion of prostate cancer cells by inducing epithelial-mesenchymal transition","volume":"12","author":"Gaballa","year":"2020","journal-title":"Cancers"},{"key":"B70","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrd3254","article-title":"Cabazitaxel","volume":"9","author":"Galsky","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B71","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jconrel.2011.12.012","article-title":"Polymeric micelles drug delivery system in oncology","volume":"159","author":"Gong","year":"2012","journal-title":"J. Control. Release"},{"key":"B73","doi-asserted-by":"publisher","first-page":"102930","DOI":"10.1016\/j.jddst.2021.102930","article-title":"Lycopene loaded polymeric nanoparticles for prostate cancer treatment: formulation, optimization using Box-behnken design and cytotoxicity studies","volume":"67","author":"Goswami","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11051-018-4407-z","article-title":"Aptamer-conjugated multi-walled carbon nanotubes as a new targeted ultrasound contrast agent for the diagnosis of prostate cancer","volume":"20","author":"Gu","year":"2018","journal-title":"J. Nanoparticle Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3892\/ijo.2013.2223","article-title":"Cisplatin-resistant prostate cancer model: differences in antioxidant system, apoptosis and cell cycle","volume":"44","author":"Gumulec","year":"2014","journal-title":"Int. J. Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/bab.2160","article-title":"Novel green synthesis and characterization of a chemotherapeutic supplement by silver nanoparticles containing Berberis thunbergii leaf for the treatment of human pancreatic cancer","volume":"69","author":"Guo","year":"2022","journal-title":"Biotechnol. Appl. Biochem."},{"key":"B77","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejps.2013.02.006","article-title":"The applications of Vitamin E TPGS in drug delivery","volume":"49","author":"Guo","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/01.cot.0000884668.75921.99","article-title":"Dostarlimab-gxly (Jemperli\u2122)","volume":"44","author":"Haarberg","year":"2022","journal-title":"Oncol. Times"},{"key":"B79","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1259\/bjr\/13169882","article-title":"Gold nanoparticles: a new X-ray contrast agent","volume":"79","author":"Hainfeld","year":"2006","journal-title":"Br. J. radiology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/00005392-200002000-00062","article-title":"High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers","volume":"163","author":"Halmos","year":"2000","journal-title":"J. Urology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ijrobp.2021.04.032","article-title":"Prostate cancer targeted X-ray fluorescence imaging via gold nanoparticles functionalized with prostate-specific membrane antigen (PSMA)","volume":"111","author":"Hara","year":"2021","journal-title":"Int. J. Radiat. Oncology* Biology* Phys."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1007\/s11095-015-1662-x","article-title":"Nano-targeted delivery of toremifene, an estrogen receptor-\u03b1 blocker in prostate cancer","volume":"32","author":"Hariri","year":"2015","journal-title":"Pharm. Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"114615","DOI":"10.1016\/j.biopha.2023.114615","article-title":"The potential application of encapsulated exosomes: a new approach to increase exosomes therapeutic efficacy","volume":"162","author":"Hazrati","year":"2023","journal-title":"Biomed. and Pharmacother."},{"key":"B84","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40364-022-00374-4","article-title":"Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications","volume":"10","author":"Hazrati","year":"2022","journal-title":"Biomark. Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/cancers12071969","article-title":"Co-expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion","volume":"12","author":"He","year":"2020","journal-title":"Cancers"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1158\/1078-0432.ccr-12-2910","article-title":"Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer","volume":"19","author":"Hoffman-Censits","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur. Urol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eururo.2014.07.035","article-title":"Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer","volume":"67","author":"Huang","year":"2015","journal-title":"Eur. Urol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a bite \u00ae immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"B90","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.radonc.2010.03.024","article-title":"Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer","volume":"95","author":"Hurwitz","year":"2010","journal-title":"Radiotherapy Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5714\/cl.2013.14.3.131","article-title":"Carbon nanotubes-properties and applications: a review","volume":"14","author":"Ibrahim","year":"2013","journal-title":"Carbon Lett."},{"key":"B92","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"B94","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.jddst.2019.101174","article-title":"Metal nanoparticles synthesis: an overview on methods of preparation, advantages and disadvantages, and applications","volume":"53","author":"Jamkhande","year":"2019","journal-title":"J. drug Deliv. Sci. Technol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/idm2.12050","article-title":"Drug delivery system based on nanobubbles","volume":"1","author":"Jin","year":"2022","journal-title":"Interdiscip. Mater."},{"key":"B96","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.colsurfb.2012.11.046","article-title":"PST-Gold nanoparticle as an effective anticancer agent with immunomodulatory properties","volume":"104","author":"Joseph","year":"2013","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"B97","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/nejmoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"18044","DOI":"10.1038\/s41598-017-18304-y","article-title":"Radiosensitization of prostate cancers in vitro and in vivo to erbium-filtered orthovoltage x-rays using actively targeted gold nanoparticles","volume":"7","author":"Khoo","year":"2017","journal-title":"Sci. Rep."},{"key":"B99","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00002371-200405000-00008","article-title":"Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer","volume":"27","author":"Ko","year":"2004","journal-title":"J. Immunother."},{"key":"B100","doi-asserted-by":"publisher","first-page":"188625","DOI":"10.1016\/j.bbcan.2021.188625","article-title":"miRNAs and androgen deprivation therapy for prostate cancer","volume":"1876","author":"Konoshenko","year":"2021","journal-title":"Biochimica Biophysica Acta (BBA)-Reviews Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.matbio.2018.08.004","article-title":"Prostate cancer sheds the \u03b1v\u03b23 integrin in vivo through exosomes","volume":"77","author":"Krishn","year":"2019","journal-title":"Matrix Biol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1800219","DOI":"10.1002\/adbi.201800219","article-title":"Biomimetic nanoparticle vaccines for cancer therapy","volume":"3","author":"Kroll","year":"2019","journal-title":"Adv. Biosyst."},{"key":"B103","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ctrv.2013.10.005","article-title":"Liposomal nanomedicines in the treatment of prostate cancer","volume":"40","author":"Kroon","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"B104","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1038\/ng1799","article-title":"Strategies to determine the biological function of microRNAs","volume":"38","author":"Kr\u00fctzfeldt","year":"2006","journal-title":"Nat. Genet."},{"key":"B105","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41417-021-00299-4","article-title":"Nanomedicine-based cancer immunotherapy: recent trends and future perspectives","volume":"28","author":"Lakshmanan","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"B106","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12951-020-00650-1","article-title":"Multifunctional nanobubbles carrying indocyanine green and paclitaxel for molecular imaging and the treatment of prostate cancer","volume":"18","author":"Lan","year":"2020","journal-title":"J. nanobiotechnology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1593\/neo.12380","article-title":"Targeted antivascular therapy with the apolipoprotein (a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model","volume":"14","author":"Lee","year":"2012","journal-title":"Neoplasia"},{"key":"B108","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","article-title":"MicroRNA delivery through nanoparticles","volume":"313","author":"Lee","year":"2019","journal-title":"J. Control. Release"},{"key":"B109","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1124\/jpet.113.207266","article-title":"NSC23766, a widely used inhibitor of Rac1 activation, additionally acts as a competitive antagonist at muscarinic acetylcholine receptors","volume":"347","author":"Levay","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1021\/bc0602127","article-title":"Synthesis of enzyme-degradable, peptide-cross-linked dextran hydrogels","volume":"18","author":"L\u00e9vesque","year":"2007","journal-title":"Bioconjugate Chem."},{"key":"B111","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1021\/jacs.0c09029","article-title":"Chemo-physical strategies to advance the in vivo functionality of targeted nanomedicine: the next generation","volume":"143","author":"Li","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"B112","first-page":"1255","article-title":"Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy","volume":"11","author":"Li","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1002\/jcb.28239","article-title":"Exosome circ_0044516 promotes prostate cancer cell proliferation and metastasis as a potential biomarker","volume":"121","author":"Li","year":"","journal-title":"J. Cell. Biochem."},{"key":"B114","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.21037\/tcr-20-1858","article-title":"Exosomal prostate-specific G-protein-coupled receptor induces osteoblast activity to promote the osteoblastic metastasis of prostate cancer","volume":"9","author":"Li","year":"","journal-title":"Transl. Cancer Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.cclet.2021.11.078","article-title":"Targeting the Rac1 pathway for improved prostate cancer therapy using polymeric nanoparticles to deliver of NSC23766","volume":"33","author":"Li","year":"2022","journal-title":"Chin. Chem. Lett."},{"key":"B116","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.biomaterials.2018.10.036","article-title":"Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer","volume":"192","author":"Lin","year":"2019","journal-title":"Biomaterials"},{"key":"B117","doi-asserted-by":"publisher","first-page":"8341","DOI":"10.3390\/ijms22158341","article-title":"Application of carbon nanoparticles in oncology and regenerative medicine","volume":"22","author":"Lisik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B118","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1517\/13543784.2011.574611","article-title":"Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer","volume":"20","author":"Liu","year":"2011","journal-title":"Expert Opin. investigational drugs"},{"key":"B119","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3892\/ijo.2014.2256","article-title":"Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells","volume":"44","author":"Liu","year":"2014","journal-title":"Int. J. Oncol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/2159-8290.cd-12-0460","article-title":"Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer","volume":"3","author":"Logothetis","year":"2013","journal-title":"Cancer Discov."},{"key":"B121","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.canlet.2017.06.036","article-title":"Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients","volume":"403","author":"Logozzi","year":"2017","journal-title":"Cancer Lett."},{"key":"B122","doi-asserted-by":"publisher","first-page":"e108925","DOI":"10.1371\/journal.pone.0108925","article-title":"Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion","volume":"9","author":"Lundholm","year":"2014","journal-title":"PloS one"},{"key":"B123","doi-asserted-by":"publisher","first-page":"8119","DOI":"10.1039\/c9sc02290b","article-title":"Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: does size matter for targeted particles?","volume":"10","author":"Luo","year":"2019","journal-title":"Chem. Sci."},{"key":"B124","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41419-023-06007-4","article-title":"Exosomal PGAM1 promotes prostate cancer angiogenesis and metastasis by interacting with ACTG1","volume":"14","author":"Luo","year":"2023","journal-title":"Cell Death and Dis."},{"key":"B125","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1021\/acsnano.8b00940","article-title":"Prostate-specific membrane antigen targeted gold nanoparticles for theranostics of prostate cancer","volume":"12","author":"Mangadlao","year":"2018","journal-title":"ACS nano"},{"key":"B126","doi-asserted-by":"publisher","first-page":"688489","DOI":"10.3389\/fonc.2021.688489","article-title":"A double-edged sword role of cytokines in prostate cancer immunotherapy","volume":"11","author":"Mao","year":"2021","journal-title":"Front. Oncol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"21276","DOI":"10.1073\/pnas.1117029108","article-title":"Molecular classification of prostate cancer using curated expression signatures","volume":"108","author":"Markert","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B128","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-019-0991-5","article-title":"Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance","volume":"18","author":"Mashouri","year":"2019","journal-title":"Mol. Cancer."},{"key":"B129","doi-asserted-by":"publisher","first-page":"5810","DOI":"10.1038\/s41467-023-41518-w","article-title":"The tumor microenvironment shows a hierarchy of cell-cell interactions dominated by fibroblasts","volume":"14","author":"Mayer","year":"2023","journal-title":"Nat. Commun."},{"key":"B130","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1038\/sj.onc.1210429","article-title":"Prostate cancer specific integrin \u03b1v\u03b23 modulates bone metastatic growth and tissue remodeling","volume":"26","author":"McCabe","year":"2007","journal-title":"Oncogene."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.2165\/11209660-000000000-00000","article-title":"Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer","volume":"72","author":"McKeage","year":"2012","journal-title":"Drugs"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00262-011-1193-1","article-title":"Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer","volume":"61","author":"McNeel","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"B133","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1756287214555336","article-title":"An update on enzalutamide in the treatment of prostate cancer","volume":"7","author":"Merseburger","year":"2015","journal-title":"Ther. Adv. Urol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1517\/14656566.2011.567268","article-title":"Cabazitaxel for the treatment of prostate cancer","volume":"12","author":"Michielsen","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2019.07.003","article-title":"Exosomes and their role in tumorigenesis and anticancer drug resistance","volume":"45","author":"Milman","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"B136","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.reactfunctpolym.2010.10.009","article-title":"Polymeric micelles for nano-scale drug delivery","volume":"71","author":"Miyata","year":"2011","journal-title":"React. Funct. Polym."},{"key":"B137","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1021\/nl0155274","article-title":"Fungus-mediated synthesis of silver nanoparticles and their immobilization in the mycelial matrix: a novel biological approach to nanoparticle synthesis","volume":"1","author":"Mukherjee","year":"2001","journal-title":"Nano Lett."},{"key":"B138","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2174\/1567201818666210224101456","article-title":"Recent trends in carbon nanotubes based prostate cancer therapy: a biomedical hybrid for diagnosis and treatment","volume":"19","author":"Murugesan","year":"2022","journal-title":"Curr. Drug Deliv."},{"key":"B139","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1021\/ar1001457","article-title":"Microwave-assisted green synthesis of silver nanostructures","volume":"44","author":"Nadagouda","year":"2011","journal-title":"Accounts Chem. Res."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.24336","article-title":"Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice","volume":"125","author":"Narayanan","year":"2009","journal-title":"Int. J. cancer"},{"key":"B141","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/a:1025461507027","article-title":"Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases","volume":"20","author":"Nemeth","year":"2003","journal-title":"Clin. and Exp. metastasis"},{"key":"B142","first-page":"293","article-title":"Mitoxantrone in multiple sclerosis","volume":"98","author":"Neuhaus","year":"2006","journal-title":"Adv. Neurology-New York-Raven Press-"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s11095-010-0233-4","article-title":"Polymeric micelles in anticancer therapy: targeting, imaging and triggered release","volume":"27","author":"Oerlemans","year":"2010","journal-title":"Pharm. Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"30357","DOI":"10.18632\/oncotarget.4851","article-title":"Identification of prostate cancer biomarkers in urinary exosomes","volume":"6","author":"\u00d8verbye","year":"2015","journal-title":"Oncotarget"},{"key":"B145","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/dddt.s13029","article-title":"Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer","volume":"5","author":"Paller","year":"2011","journal-title":"Drug Des. Dev. Ther."},{"key":"B146","doi-asserted-by":"publisher","first-page":"97693","DOI":"10.18632\/oncotarget.18532","article-title":"Exosomes in diagnosis and therapy of prostate cancer","volume":"8","author":"Pan","year":"2017","journal-title":"Oncotarget"},{"key":"B147","doi-asserted-by":"publisher","first-page":"120946","DOI":"10.1016\/j.biomaterials.2021.120946","article-title":"Urinary exosomes-based engineered nanovectors for homologously targeted chemo-chemodynamic prostate cancer therapy via abrogating EGFR\/AKT\/NF-kB\/IkB signaling","volume":"275","author":"Pan","year":"2021","journal-title":"Biomaterials"},{"key":"B148","doi-asserted-by":"publisher","first-page":"15647","DOI":"10.1039\/c9nr04828f","article-title":"Contrast enhanced ultrasound imaging by nature-inspired ultrastable echogenic nanobubbles","volume":"11","author":"Perera","year":"2019","journal-title":"Nanoscale"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/nejmoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B150","first-page":"3","article-title":"Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer","volume-title":"Seminars in oncology","author":"Pienta","year":"2001"},{"key":"B151","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2012.10.002","article-title":"Natural history of early, localized prostate cancer: a final report from three decades of follow-up","volume":"63","author":"Popiolek","year":"2013","journal-title":"Eur. Urol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"110126","DOI":"10.1016\/j.cellsig.2021.110126","article-title":"Pro-angiogenic effect of PC-3 exosomes in endothelial cells in vitro","volume":"87","author":"Prigol","year":"2021","journal-title":"Cell. Signal."},{"key":"B153","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41401-020-0423-5","article-title":"Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells","volume":"41","author":"Qi","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"B154","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.etap.2016.09.015","article-title":"The biological activity of cationic liposomes in drug delivery and toxicity test in animal models","volume":"47","author":"Qi","year":"2016","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1093\/annonc\/mdx348","article-title":"The evolution of chemotherapy for the treatment of prostate cancer","volume":"28","author":"Quinn","year":"2017","journal-title":"Ann. Oncol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s13346-022-01241-3","article-title":"Nanocarriers for cancer nano-immunotherapy","volume":"13","author":"Rana","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"B157","doi-asserted-by":"publisher","first-page":"127144","DOI":"10.1016\/j.colsurfa.2021.127144","article-title":"PCL-TPGS polymeric nanoparticles for docetaxel delivery to prostate cancer: development, physicochemical and biological characterization","volume":"627","author":"Raspantini","year":"2021","journal-title":"Colloids Surfaces A Physicochem. Eng. Aspects"},{"key":"B158","doi-asserted-by":"publisher","first-page":"110804","DOI":"10.1016\/j.colsurfb.2020.110804","article-title":"pH-responsive cationic liposome for endosomal escape mediated drug delivery","volume":"188","author":"Rayamajhi","year":"2020","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"B159","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1517\/14656566.2013.834328","article-title":"Agonists of luteinizing hormone-releasing hormone in prostate cancer","volume":"14","author":"Rick","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"B160","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1166\/jbn.2014.1758","article-title":"Carbon nanofibers and carbon nanotubes sensitize prostate and bladder cancer cells to platinum-based chemotherapeutics","volume":"10","author":"Ringel","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"375101","DOI":"10.1088\/0957-4484\/20\/37\/375101","article-title":"Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle","volume":"20","author":"Roa","year":"2009","journal-title":"Nanotechnology"},{"key":"B162","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s11671-021-03553-8","article-title":"Liposomal nanomedicine: applications for drug delivery in cancer therapy","volume":"16","author":"Rommasi","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"B163","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"B164","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41391-019-0176-8","article-title":"A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer","volume":"23","author":"Ross","year":"2020","journal-title":"Prostate cancer prostatic Dis."},{"key":"B165","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/s1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jconrel.2015.09.031","article-title":"Microvesicle-and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells","volume":"220","author":"Saari","year":"2015","journal-title":"J. Control. release"},{"key":"B167","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.bios.2012.10.053","article-title":"Highly sensitive immunosensing of prostate-specific antigen based on ionic liquid\u2013carbon nanotubes modified electrode: application as cancer biomarker for prostatebiopsies","volume":"42","author":"Salimi","year":"2013","journal-title":"Biosens. Bioelectron."},{"key":"B168","doi-asserted-by":"publisher","first-page":"104212","DOI":"10.1016\/j.jddst.2023.104212","article-title":"Recent advances and futuristic potentials of nano-tailored doxorubicin for prostate cancer therapy","volume":"81","author":"Sawpari","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s40425-019-0741-7","article-title":"CAR-T cell therapy: a potential new strategy against prostate cancer","volume":"7","author":"Schepisi","year":"2019","journal-title":"J. Immunother. cancer"},{"key":"B170","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2165\/00023210-200418060-00010","article-title":"Mitoxantrone: a review of its use in multiple sclerosis","volume":"18","author":"Scott","year":"2004","journal-title":"CNS drugs"},{"key":"B171","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.seminoncol.2018.01.003","article-title":"The surgical management of prostate cancer","volume":"44","author":"Sebesta","year":"2017","journal-title":"Seminars in oncology"},{"key":"B172","doi-asserted-by":"publisher","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"B173","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jconrel.2020.12.017","article-title":"Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo","volume":"330","author":"Severic","year":"2021","journal-title":"J. Control. release"},{"key":"B174","doi-asserted-by":"publisher","first-page":"111035","DOI":"10.1016\/j.msec.2020.111035","article-title":"LHRH-conjugated, PEGylated, poly-lactide-co-glycolide nanocapsules for targeted delivery of combinational chemotherapeutic drugs Docetaxel and Quercetin for prostate cancer","volume":"114","author":"Shitole","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"key":"B175","doi-asserted-by":"publisher","first-page":"12426","DOI":"10.1073\/pnas.1121174109","article-title":"Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer","volume":"109","author":"Shukla","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B176","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.urolonc.2005.08.021","article-title":"Granulocyte-macrophage colony-stimulating factor\u2212 transduced allogeneic cancer cellular immunotherapy: the GVAX\u00ae vaccine for prostate cancer","volume":"24","author":"Simons","year":"2006","journal-title":"Urologic oncology: seminars and original investigations"},{"key":"B177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ma13010001","article-title":"Methods of gold and silver nanoparticles preparation","volume":"13","author":"Slepi\u010dka","year":"2019","journal-title":"Materials"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.carbon.2005.10.011","article-title":"The biocompatibility of carbon nanotubes","volume":"44","author":"Smart","year":"2006","journal-title":"Carbon"},{"key":"B179","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3816\/clm.2008.n.001","article-title":"Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin","volume":"8","author":"Solomon","year":"2008","journal-title":"Clin. lymphoma myeloma"},{"key":"B180","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.actbio.2020.03.034","article-title":"Biogenic nanobubbles for effective oxygen delivery and enhanced photodynamic therapy of cancer","volume":"108","author":"Song","year":"2020","journal-title":"Acta biomater."},{"key":"B181","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.suronc.2009.07.001","article-title":"History of prostate cancer treatment","volume":"18","author":"Sriprasad","year":"2009","journal-title":"Surg. Oncol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s12274-017-1518-2","article-title":"Surface chemistry of carbon nanoparticles functionally select their uptake in various stages of cancer cells","volume":"10","author":"Srivastava","year":"2017","journal-title":"Nano Res."},{"key":"B183","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrg3471","article-title":"Adult-specific functions of animal microRNAs","volume":"14","author":"Sun","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"B184","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41401-020-0448-9","article-title":"Cancer nanomedicine meets immunotherapy: opportunities and challenges","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"B185","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced prostate cancer: treatment advances and future directions","volume":"6","author":"Swami","year":"2020","journal-title":"Trends cancer"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann. Oncol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"13015","DOI":"10.1021\/acsnano.9b05679","article-title":"Overcoming the reticuloendothelial system barrier to drug delivery with a \u201cdon\u2019t-eat-us\u201d strategy","volume":"13","author":"Tang","year":"2019","journal-title":"ACS nano"},{"key":"B188","doi-asserted-by":"publisher","first-page":"100964","DOI":"10.1016\/j.nantod.2020.100964","article-title":"Efficient encapsulation of biocompatible nanoparticles in exosomes for cancer theranostics","volume":"35","author":"Tanziela","year":"2020","journal-title":"Nano Today"},{"key":"B189","doi-asserted-by":"publisher","first-page":"8809","DOI":"10.1073\/pnas.1019330108","article-title":"Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer","volume":"108","author":"Tavoosidana","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B190","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3892\/etm.2011.286","article-title":"Serum cytokine profiles in patients with prostate carcinoma","volume":"2","author":"Tazaki","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1503\/cmaj.060955","article-title":"Prostate-specific antigen in the early detection of prostate cancer","volume":"176","author":"Thompson","year":"2007","journal-title":"Cmaj"},{"key":"B192","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1073\/pnas.79.5.1658","article-title":"Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists","volume":"79","author":"Tolis","year":"1982","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B193","first-page":"8511","article-title":"Significance of MMP-2 expression in prostate cancer: an immunohistochemical study","volume":"63","author":"Trudel","year":"2003","journal-title":"Cancer Res."},{"key":"B194","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1442-2042.2012.02997.x","article-title":"Gonadotropin\u2010releasing hormone: an update review of the antagonists versus agonists","volume":"19","author":"Van Poppel","year":"2012","journal-title":"Int. J. urology"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/cncr.1980.45.s7.1906","article-title":"Radical surgery for prostatic cancer","volume":"45","author":"Walsh","year":"1980","journal-title":"Cancer."},{"key":"B196","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bios.2011.08.033","article-title":"Carbon nanotube-based ultrasensitive multiplexing electrochemical immunosensor for cancer biomarkers","volume":"30","author":"Wan","year":"2011","journal-title":"Biosens. Bioelectron."},{"key":"B197","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jconrel.2014.10.012","article-title":"RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer","volume":"196","author":"Wang","year":"2014","journal-title":"J. Control. Release"},{"key":"B198","first-page":"210","article-title":"Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy","volume":"10","author":"Wang","year":"2022","journal-title":"Am. J. Clin. Exp. urology"},{"key":"B199","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jconrel.2020.10.020","article-title":"Challenges in the development and establishment of exosome-based drug delivery systems","volume":"329","author":"Wang","year":"2021","journal-title":"J. Control. Release"},{"key":"B200","doi-asserted-by":"publisher","first-page":"109109","DOI":"10.1016\/j.biopha.2019.109109","article-title":"Prostate carcinoma cell-derived exosomal MicroRNA-26a modulates the metastasis and tumor growth of prostate carcinoma","volume":"117","author":"Wang","year":"2019","journal-title":"Biomed. and Pharmacother."},{"key":"B201","doi-asserted-by":"publisher","first-page":"114895","DOI":"10.1016\/j.addr.2023.114895","article-title":"Stealth and pseudo-stealth nanocarriers","volume":"198","author":"Wen","year":"2023","journal-title":"Adv. drug Deliv. Rev."},{"key":"B202","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fimmu.2014.00191","article-title":"Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens","volume":"5","author":"Westdorp","year":"2014","journal-title":"Front. Immunol."},{"key":"B203","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2005.07.008","article-title":"Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention","volume":"16","author":"Whiteside","year":"2006","journal-title":"Seminars in cancer biology"},{"key":"B204","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/bs.acc.2015.12.005","article-title":"Tumor-derived exosomes and their role in cancer progression","volume":"74","author":"Whiteside","year":"2016","journal-title":"Adv. Clin. Chem."},{"key":"B205","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41585-021-00488-8","article-title":"The potential of CAR T cell therapy for prostate cancer","volume":"18","author":"Wolf","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.nano.2014.12.016","article-title":"Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo","volume":"11","author":"Wolfe","year":"2015","journal-title":"Nanomedicine Nanotechnol. Biol. Med."},{"key":"B207","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/85438","article-title":"Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming","volume":"7","author":"Wolfers","year":"2001","journal-title":"Nat. Med."},{"key":"B208","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1016\/j.biomaterials.2014.03.038","article-title":"Prostate stem cell antigen antibody-conjugated multiwalled carbon nanotubes for targeted ultrasound imaging and drug delivery","volume":"35","author":"Wu","year":"2014","journal-title":"Biomaterials"},{"key":"B209","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.2147\/ijn.s136032","article-title":"Paclitaxel-loaded and A10-3.2 aptamer-targeted poly (lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer","volume":"12","author":"Wu","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"B210","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/10717544.2017.1422300","article-title":"Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer","volume":"25","author":"Wu","year":"2018","journal-title":"Drug Deliv."},{"key":"B211","doi-asserted-by":"publisher","first-page":"5244","DOI":"10.1016\/j.biomaterials.2013.03.006","article-title":"Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer","volume":"34","author":"Xu","year":"2013","journal-title":"Biomaterials"},{"key":"B212","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.biopha.2016.12.138","article-title":"Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer","volume":"88","author":"Yan","year":"2017","journal-title":"Biomed. and Pharmacother."},{"key":"B213","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3109\/10717544.2015.1069423","article-title":"Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid\u2013polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo","volume":"23","author":"Yan","year":"2016","journal-title":"Drug Deliv."},{"key":"B214","doi-asserted-by":"publisher","first-page":"94834","DOI":"10.18632\/oncotarget.22014","article-title":"Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer","volume":"8","author":"Ye","year":"2017","journal-title":"Oncotarget"},{"key":"B215","doi-asserted-by":"publisher","first-page":"914875","DOI":"10.3389\/fonc.2022.914875","article-title":"Causes of death among prostate cancer patients aged 40 years and older in the United States","volume":"12","author":"Ye","year":"2022","journal-title":"Front. Oncol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1038\/s41467-019-11718-4","article-title":"Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy","volume":"10","author":"Yong","year":"2019","journal-title":"Nat. Commun."},{"key":"B217","doi-asserted-by":"publisher","first-page":"37151","DOI":"10.18632\/oncotarget.6022","article-title":"Tumor-derived exosomes in cancer progression and treatment failure","volume":"6","author":"Yu","year":"2015","journal-title":"Oncotarget"},{"key":"B218","doi-asserted-by":"publisher","first-page":"e3376","DOI":"10.1002\/jgm.3376","article-title":"Inhibition of circ_0081234 reduces prostate cancer tumor growth and metastasis via the miR\u20101\/MAP 3 K1 axis","volume":"24","author":"Zhang","year":"2022","journal-title":"J. Gene Med."},{"key":"B219","doi-asserted-by":"publisher","first-page":"E160","DOI":"10.25011\/cim.v31i3.3473","article-title":"Enhanced radiation sensitivity in prostate cancer by gold-nanoparticles","volume":"31","author":"Zhang","year":"2008","journal-title":"Clin. Investigative Med."},{"key":"B220","doi-asserted-by":"publisher","first-page":"1902542","DOI":"10.1002\/adma.201902542","article-title":"In situ modification of the tumor cell surface with immunomodulating nanoparticles for effective suppression of tumor growth in mice","volume":"31","author":"Zheng","year":"2019","journal-title":"Adv. Mater."},{"key":"B221","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/ijc.30670","article-title":"Early detection of pancreatic cancer: where are we now and where are we going?","volume":"141","author":"Zhou","year":"2017","journal-title":"Int. J. cancer"},{"key":"B222","doi-asserted-by":"publisher","first-page":"11595","DOI":"10.2147\/ott.s272869","article-title":"Functional implication of exosomal miR-217 and miR-23b-3p in the progression of prostate cancer","volume":"13","author":"Zhou","year":"2020","journal-title":"OncoTargets Ther."},{"key":"B223","doi-asserted-by":"publisher","first-page":"1805888","DOI":"10.1002\/adma.201805888","article-title":"Tumor microenvironment\u2010activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade","volume":"31","author":"Zhou","year":"2019","journal-title":"Adv. Mater."},{"key":"B224","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.2217\/nnm-2020-0188","article-title":"Magnetic polymeric nanobubbles with optimized core size for MRI\/ultrasound bimodal molecular imaging of prostate cancer","volume":"15","author":"Zhu","year":"2020","journal-title":"Nanomedicine"},{"key":"B225","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/pros.20065","article-title":"The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial","volume":"60","author":"Ziada","year":"2004","journal-title":"Prostate"},{"key":"B226","doi-asserted-by":"publisher","first-page":"1801120","DOI":"10.1002\/smll.201801120","article-title":"A multifunctional biomimetic nanoplatform for relieving hypoxia to enhance chemotherapy and inhibit the PD\u20101\/PD\u2010L1 axis","volume":"14","author":"Zou","year":"2018","journal-title":"Small"}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2024.1444201\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T11:59:53Z","timestamp":1725969593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2024.1444201\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":226,"alternative-id":["10.3389\/fbioe.2024.1444201"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2024.1444201","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"article-number":"1444201"}}